Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Mangel A, Lothman K. Commentary: emergence of a new paradigm in understanding the cardiovascular system: pulse synchronized contractions. Cardiovasc Pharm Open Access. 2017;6(5):220. doi: 10.4172/2329-6607.1000220
Warttig SL, Forshaw MJ, South J, White AK. New, normative, English-sample data for the Short Form Perceived Stress Scale (PSS-4). J Health Psychol. 2013 Dec;18(12):1617-28. doi: 10.1177/1359105313508346
Melendez J, Galli I, Boric K, Ortega A, Zuniga L, Henriquez-Roldan CF, Cardenas AM. Zolpidem and triazolam do not affect the nocturnal sleep-induced memory improvement. Psychopharmacology (Berl). 2005 Aug;181(1):21-6. doi: 10.1007/s00213-005-2228-0
Dykstra LA, Granger AL, Allen RM, Zhang X, Rice KC. Antinociceptive effects of the selective delta opioid agonist SNC80 alone and in combination with mu opioids in the squirrel monkey titration procedure. Psychopharmacology (Berl). 2002 Oct 1;163(3-4):420-9.